<DOC>
	<DOCNO>NCT01156298</DOCNO>
	<brief_summary>Phase IV , multi-center , non-treatment , observational , registry study determine long term effect AVONEX® therapy EDSS , MRI , QoL , cognition .</brief_summary>
	<brief_title>Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance</brief_title>
	<detailed_description>The primary objective study determine impact long term AVONEX® treatment physical status , measure expand disability scale score ( EDSS ) , patient Multiple Sclerosis ( MS ) first clinical event ( clinically isolate syndrome ) Magnetic Resonance Imaging ( MRI ) consistent MS . Secondary objective determine impact long term therapy AVONEX® following : ) MRI parameters- new enlarge T2 lesion , T2 lesion volume , T1 lesion volume , brain parenchymal fraction ( BPF ) b ) Quality Life ( QoL ) : Heath Status Questionnaire ( SF-36 ) c ) Symbol Digit Modality Test ( SDMT ) 2 . To determine long term impact therapy follow patient treated onset clinically isolated event ( CIS ) 1 . EDSS 2 . MRI parameters 3 . SF-36 4 . SDMT 3 . To determine early clinical MRI predictor disease progression . Approximately 383 patient participate CHAMPS , original AVONEX® placebo trial , approach study participation . The patient population divide two cohort . Cohort 1 : Patients participate CHAMPS CHAMPIONS 10 approach study participation approximately twenty-four CHAMPIONS Continuation investigative site . Cohort 2 : Patients participate CHAMPS locate approach study participation . Patient participate CHAMPIONS 10 exclude Cohort 2 . Efforts make potentially locate patient either original CHAMPS investigative site , Biogen Idec patient service database , and/or third party ( i.e. , patient location service vendor ) combination three . . For cohort , public database may utilize patient report death .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Patients eligible screen study follow criterion meet : 1 . All patient must originally enrol CHAMPS , regardless randomization arm . Only Cohort 1 patient must enrol CHAMPIONS 10 . 2 . Willing able provide inform consent ( Cohort 1 ) , waiver inform consent ( Cohort 2 ) , report patient death public database search . 3 . Ability read write English ( patient report assessment tool English ) . Candidates exclude study screen follow exclusion criterion exist : 1 . Patients participate original CHAMPS study . 2 . Alternative diagnosis MS discover . 3 . Patient unwilling unable provide inform consent ( Cohort 1 ) waiver inform consent ( Cohort 2 ) , applicable . 4 . Any reason , opinion Investigator ( Cohort 1 ) Patient Coordination Center ( Cohort 2 ) , patient determine unsuitable enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>